Insegia (PAS) / Cancer Advances - LARVOL DELTA

Cancer Advances, Inc. Announces Issuance of New U.S. Patent (GlobeNewswire) - "Cancer Advances, Inc...announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator (PAS) vaccine. The new patent titled 'Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer' covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject. Gastrin mediated tumors include, but are not limited to, gastrointestinal cancers."

Patent • Gastrointestinal Cancer • Oncology • Solid Tumor

Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer. (PubMed, Front Oncol) - "CCK-BR expression was identified in samples from a human tissue array by immunohistochemistry confirming the clinical relevance of this study. These results confirm the significance of the gastrin-CCK-BR signaling pathway in gastric cancer and suggest that the addition of a gastrin vaccine, PAS, to therapy with an immune checkpoint antibody may decrease growth and metastases of gastric cancer by altering the tumor microenvironment."

Combination therapy • IO biomarker • Journal • Fibrosis • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Immune Modulation • Immunology • Inflammation • Oncology • Solid Tumor • CD8 • GAST • PD-L1

Role of an anti-gastrin vaccine (PAS) alone and in combination with a PD-1 antibody on growth and metastases of gastric cancer. (ASCO-GI 2022) - "Treatment of mice with an anti-gastrin vaccine, PAS, slows growth of gastric cancer and prevents metastases. PAS vaccination improves the effectiveness of PD-1 Ab therapy in part by decreasing tumor fibrosis and altering the tumor immune cell signature. This study suggests that addition of PAS to immune checkpoint antibody therapy in gastric cancer may be beneficial."

Combination therapy • IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CCKBR • CD8 • GAST • PD-L1

Cancer Advances, Inc. Announces Abstract and Poster Presentation at ASCO GI – Role of an anti-gastrin vaccine (PAS) in combination with a PD-1 antibody on growth and metastasis of gastric cancer (GlobeNewswire) - "The researchers evaluated the effect of Cancer Advances’ Polyclonal Antibody Stimulator (PAS) vaccine and PD-1 antibody therapy alone or in combination in a murine model of gastric cancer. PAS monotherapy was found to significantly decrease tumor growth rate and fibrosis in the tumor microenvironment, and to eliminate metastases. The impact of combination therapy on these factors was greater still, although PD-1 therapy alone was not significantly different from placebo."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in Oncology (GlobeNewswire) - "Tumor growth was significantly slower than controls in PAS-treated mice, and tumor growth rate was decreased even more in combination-treated mice. There were no metastases in any of the mice treated with PAS either alone or in combination with PD-1 Ab. PAS monotherapy or combined with PD-1 Ab increased tumor CD8+ T-lymphocytes and decreased the number of immunosuppressive M2-polarized tumor-associated macrophages."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology

Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention Research (GlobeNewswire) - “Cancer Advances, Inc…The published study demonstrates the impact of PAS vaccine using a KRAS mouse model known to develop precancerous pancreatic intraepithelial neoplasia (PanIN) lesions and pancreatic cancer over time. The studies show that PAS vaccination significantly decreased high grade PanIN lesions and altered the pancreas microenvironment rendering it less carcinogenic. (i) High grade PanIN-3 lesions were significantly less in PAS-treated mice (P=0.0077), and cancers developed in 33% of the control mice but only in 10% of the PAS-treated mice (ii) Compared to the control mice, fibrosis was reduced by >50%, arginase positive M2 macrophages were reduced by 74%, and CD8+ T-cells were increased by 73% in the pancreas extracellular matrix in PAS-treated mice.”

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model“ in Cancer Prevention Research (GlobeNewswire) - "The published study demonstrates the impact of PAS vaccine using a KRAS mouse model known to develop precancerous pancreatic intraepithelial neoplasia (PanIN) lesions and pancreatic cancer over time. The studies show that PAS vaccination significantly decreased high grade PanIN lesions and altered the pancreas microenvironment rendering it less carcinogenic....PAS is a phase 3 ready cancer vaccine that induces antibodies to gastrin, a known stimulator of pancreatic cancer."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Cancer Advances, Inc. Announces Publication, 'Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model' in Cancer Prevention Research (GlobeNewswire) - "High grade PanIN-3 lesions were significantly less in PAS-treated mice (P=0.0077), and cancers developed in 33% of the control mice but only in 10% of the PAS-treated mice...Compared to the control mice, fibrosis was reduced by >50%, arginase positive M2 macrophages were reduced by 74%, and CD8+ T-cells were increased by 73% in the pancreas extracellular matrix in PAS-treated mice."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Cancer Advances, Inc. Announces Minisymposium Presentation at AACR (GlobeNewswire) - "Cancer Advances...announces that its abstract entitled, 'Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse model' has been selected for presentation in a minisymposium at the AACR Annual Meeting 2021. Jill Smith, MD of the Georgetown Lombardi Comprehensive Cancer Center, will present the results of this study during the week of April 10-15, 2021."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Cancer Advances, Inc. Announces Abstract at AACR (GlobeNewswire) - “Cancer Advances, Inc…announces that an abstract will be included in the upcoming 2021 American Association of Cancer Research (AACR) Annual Meeting being held virtually from April 10-15, 2021. The abstract is entitled, ‘Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse model’ and is available at the AACR meeting website.”

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma (clinicaltrials.gov) - P3; N=394; Completed; Sponsor: Cancer Advances Inc.; Active, not recruiting -> Completed

Trial completion • Biosimilar • Oncology • Pancreatic Cancer

Vaccine Against Gastrin, Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases. (PubMed, Am J Physiol Gastrointest Liver Physiol) - "In the current investigation, we studied the effects of an anti-gastrin cancer vaccine, polyclonal antibody stimulator (PAS; formerly called G17DT and Gastrimmune), used alone or in combination with a programmed cell death receptor (PD)-1 immune checkpoint antibody on pancreatic cancer growth, metastases, and the tumor microenvironment (TME)...PAS vaccine appears to change the tumor microenvironment, making it more susceptible to therapy with an immune checkpoint antibody. This novel combination of two immunotherapies may improve survival of pancreatic cancer by decreasing both tumor growth and metastasis formation."

IO Biomarker • Journal • Fibrosis • Gastrointestinal Cancer • Immune Modulation • Immunology • Inflammation • Oncology • Pancreatic Cancer • Solid Tumor